Q-omics provides the consensus-scored ZBTB20 profile across patient tissues and cancer cell-line models. ZBTB20 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ZBTB20 is differentially expressed in 9, with the highest sampling consensus in THCA. Additionally, ZBTB20 protein abundance shows 26,491 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRC, THCA, and LSCC as cancer lineages where ZBTB20 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZBTB20 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZBTB20 survival associations across molecular data types. ZBTB20 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (6) and mass-spec protein abundance (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZBTB20 RNA expression–survival associations across cancer types. High ZBTB20 expression shows unfavorable associations in COAD, SCLC, ACC and THCA, but favorable associations in KIRC and UVM. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ZBTB20 RNA expression.
This table summarizes ZBTB20 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 7. The strongest signals are observed in THCA for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for ZBTB20. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZBTB20 shows lower tumor expression in THCA, BRCA, LUSC, KICH and UCEC and higher tumor expression in LIHC. The THCA box plot shows higher ZBTB20 RNA expression in normal versus tumor tissue (log2 FC = −0.585, t-test p < 0.001).
This table shows molecular features associated with ZBTB20 in patient tissues and cancer cell lines. In patient samples, ZBTB20 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, ZBTB20 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Myeloma and BLOOD_Leukemia.
